Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.56 |
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | RECQL | P46063 | 6/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.56 |
| ▸ | TP53 | P04637 | 6/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.56 |
| ▸ | CDK2 | P24941 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.56 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.56 |
| ▸ | APP | P05067 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976811 | 1.00 | MEN1 (0.56) | MEN1KMT2AKDM4ECYP3A4HSD17B10 | |
| SCHEMBL12557449 | 0.90 | MAPT (0.45) | MEN1KMT2AKDM4ECYP3A4HSD17B10 | |
| SCHEMBL12557457 | 0.90 | MAPT (0.45) | MEN1KMT2AKDM4ECYP3A4HSD17B10 | |
| SCHEMBL1421624 | 0.87 | MAPT (0.61) | MEN1KMT2AKDM4ECYP3A4HSD17B10 | |
| SCHEMBL1974001 | 0.84 | CDK2 (0.52) | MEN1KMT2AKDM4ECYP3A4HSD17B10 | |
| SCHEMBL1975543 | 0.84 | CDK2 (0.52) | MEN1KMT2AKDM4ECYP3A4HSD17B10 | |
| SCHEMBL1421468 | 0.84 | MEN1 (0.57) | MEN1KMT2AKDM4ECYP3A4HSD17B10 | |
| SCHEMBL12557441 | 0.84 | MEN1 (0.57) | MEN1KMT2AKDM4ECYP3A4HSD17B10 | |
| SCHEMBL10037939 | 0.81 | MEN1 (0.76) | MEN1KMT2AKDM4ECYP3A4HSD17B10 | |
| SCHEMBL1972783 | 0.81 | MAPT (0.61) | MEN1KMT2AKDM4ECYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AXOGLIA THERAPEUTICS (LU) | 2011-06-16 | — | — | US | disclosed |
| EP-2112145-A1 | Chromenone derivatives useful for the treatment of neurodegenerative diseases | AxoGlia Therapeutics S.A. (LU) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, CDR2, SNCA | MEN1 1507/4885KMT2A 3801/4885KDM4E 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.